Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.

Clinical and experimental rheumatology - 1 Jan 2000

Soukup Tomas, Dosedel Martin, Nekvindova Jana, Toms Jan, Vlcek Jiri, Pavek Petr

Abstract excerpt

Leflunomide (LEF) is a disease-modifying anti-rheumatic drug used for treating rheumatoid arthritis (RA). More than 50% of patients are withdrawn from LEF treatment within one year, mainly due to AEs. Importantly, it is not possible to predict which patients will respond to LEF therapy nor if adverse outcome occurs. Pharmacogenetic studies indicate an impact of single nucleotid polymorphisms (SNPs) on the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 Enzyme System
Share to Antirheumatic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Share to ATP-Binding Cassette Transporters

Share to Biotransformation

Share to Isoxazoles

Share to Oxidoreductases Acting on CH-CH Group Donors

Share to Receptors, Estrogen

Source

Identifiers

PMID: 25664505

Genes

DHODH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphisms in metabolic pathways of leflunomide in the treatment of rheumatoid arthritis.PMID 25664505Read ↗

Frequency and impact of DHODH, ABCG2 and CYP2C19 SNPs on the therapeutic efficacy, tolerability and toxicity of leflunomide.Semantic proximity Read ↗

Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patientsSemantic proximity Read ↗

Dihydroorotate dehydrogenase polymorphism influences the toxicity of leflunomide treatment in patients with rheumatoid arthritisSemantic proximity Read ↗

Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis.Semantic proximity Read ↗

The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide.Semantic proximity Read ↗

Genetic polymorphisms affect efficacy and adverse drug reactions of DMARDs in rheumatoid arthritis.Semantic proximity Read ↗

Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.Semantic proximity Read ↗

Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.Semantic proximity Read ↗

The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide.Semantic proximity Read ↗

Pharmacogenetics of disease-modifying anti-rheumatic drugs.Semantic proximity Read ↗

Lack of association between CYB5A gene rs1790834 polymorphism and the response to leflunomide in women with rheumatoid arthritis.Semantic proximity Read ↗

Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.